News related to Brimonidine ( Ophthalmic) and/or conditions it is approved for
ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data At The 2009 Annual Meeting Of The American College Of Allergy, Asthma & Immunology (ACAAI)
Source: Allergy News From Medical News Today [2009.11.10]
ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), announced additional results from the Company's Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5% Phase 3 clinical studies. These results were presented in poster sessions at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Miami Beach, FL. In a poster presentation titled, "Treatment of Ocular Itching with Bepotastine Besilate Ophthalmic Solution 1.
ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data At The American College Of Clinical Pharmacy (ACCP) 2009 Annual Meeting
Source: Allergy News From Medical News Today [2009.10.22]
ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) announced poster presentations of results from the Company's Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5% Phase 3 clinical studies in allergic conjunctivitis. The studies demonstrated Bepreve was safe and well-tolerated when given twice daily for six weeks in a healthy pediatric population as young as three years of age.
|
